Consensus Statement on Proton Therapy in Mesothelioma

International Particle Therapy Cooperative Group Thoracic Subcommittee; Zeng, Jing; Badiyan, Shahed N.; Garces, Yolanda I.; Wong, Tony; Zhang, Xiaodong; Simone, Charles B.; Chang, Joe Y.; Knopf, Antje C.; Mori, Shinichiro

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2021

Citation for published version (APA):
International Particle Therapy Cooperative Group Thoracic Subcommittee, Zeng, J., Badiyan, S. N., Garces, Y. I., Wong, T., Zhang, X., Simone, C. B., Chang, J. Y., Knopf, A. C., Mori, S., Iwata, H., Meijers, A., Li, H., Bues, M., Liu, W., Schild, S. E., & Rengan, R. (2021). Consensus Statement on Proton Therapy in Mesothelioma. *Practical radiation oncology*, *11*(2), 119-133. https://doi.org/10.1016/j.prro.2020.05.004

practical radiation oncology®

pro

www.practicalradonc.org

Critical Review

Consensus Statement on Proton Therapy in Mesothelioma

Jing Zeng, MD,[a],[*] Shahed N. Badiyan, MD,[b] Yolanda I. Garces, MD,[c]
Tony Wong, PhD,[d] Xiaodong Zhang, PhD,[e] Charles B. Simone, 2nd, MD,[f]
Joe Y. Chang, MD, PhD,[g] Antje C. Knopf, PhD,[h] Shinichiro Mori, PhD,[i]
Hiromitsu Iwata, MD, PhD,[j] Arturs Meijers, MS,[h] Heng Li, PhD,[k]
Martin Bues, PhD,[l] Wei Liu, PhD,[l] Steven E. Schild, MD,[l] and
Ramesh Rengan, MD, PhD,[a] on behalf of the International Particle Therapy
Cooperative Group Thoracic Subcommittee

[a]Department of Radiation Oncology, University of Washington School of Medicine, Seattle, Washington; [b]Department of
Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri; [c]Department of Radiation
Oncology, Mayo Clinic Rochester, Rochester, Minnesota; [d]Seattle Cancer Care Alliance Proton Therapy Center, Seattle,
Washington; [e]Department of Radiation Physics, Division of Radiation Oncology, University of Texas MD Anderson
Cancer Center, Houston, Texas; [f]New York Proton Center, New York, New York; [g]Department of Radiation Oncology,
Division of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas; [h]Division of
Radiotherapy, University of Groningen, Groningen, Netherlands; [i]Research Center for Charged Particle Therapy,
National Institute of Radiological Sciences, Chiba, Japan; [j]Department of Radiation Oncology, Nagoya Proton Therapy
Center, Nagoya City West Medical Center, Nagoya, Japan; [k]Department of Radiation Oncology and Molecular Radiation
Sciences, Johns Hopkins Medicine, Baltimore, Maryland; [l]Department of Radiation Oncology, Mayo Clinic Arizona,
Scottsdale, Arizona

Abstract

Purpose: Radiation therapy for mesothelioma remains challenging, as normal tissue toxicity limits the amount of radiation that can be safely delivered to the pleural surfaces, especially radiation dose to the contralateral lung. The physical properties of proton therapy result in better sparing of normal tissues when treating the pleura, both in the postpneumonectomy setting and the lung-intact setting. Compared with photon radiation, there are dramatic reductions in dose to the contralateral lung, heart, liver, kidneys, and stomach. However, the tissue heterogeneity in the thorax, organ motion, and potential for changing anatomy during the treatment course all present challenges to optimal irradiation with protons.

Methods: The clinical data underlying proton therapy in mesothelioma are reviewed here, including indications, advantages, and limitations.
Results: The Particle Therapy Cooperative Group Thoracic Subcommittee task group provides specific guidelines for the use of proton therapy for mesothelioma.
Conclusions: This consensus report can be used to guide clinical practice, insurance approval, and future research.

Introduction

Mesothelioma is an uncommon malignancy with approximately 2500 cases per year in the United States[1] and around 10,000 cases in North America, Western Europe, Japan, and Australia combined.[2] Generally, prognosis is poor, with a median survival of about 1 year.[3] The most commonly used treatment options include chemotherapy or immunotherapy, surgery, and radiation therapy, either alone or in combination. Treatment is dependent on several clinical factors, including extent of disease, performance status, baseline pulmonary function, and tumor histology. Significant toxicities are associated with the currently available treatment options, and optimal management is controversial. The 2 main surgical options for mesothelioma are extrapleural pneumonectomy (EPP) and extended pleurectomy and decortication (P/D). Resection carries substantial risk, with perioperative mortality of 12.5% in a randomized trial of EPP and at least 3.4% to 7.0% even in high-volume centers.[4-7] P/D is generally better tolerated than EPP but is still associated with a 3.1% postoperative mortality in the Society of Thoracic Surgeons Database and 4% in a separate large series from Memorial Sloan Kettering Cancer Center (MSKCC).[6,7] EPP was considered standard of care for patients with resectable disease, but the MARS trial called into question the role of EPP versus chemotherapy alone, and retrospective series have suggested that P/D may lead to survival superior to EPP.[5,7,8]

Radiation therapy for mesothelioma also carries substantial risks of toxicity. Radiation can be given in several scenarios: (1) hemithoracic radiation post-EPP; (2) hemithoracic radiation with an intact ipsilateral lung, either as definitive radiation, post-P/D adjuvant radiation, or neoadjuvant radiation before planned resection; (3) palliative radiation to focal areas as needed; and (4) as prophylactic irradiation of surgical tract sites.[9,10] Regardless of whether patients have an intact ipsilateral lung or are post-EPP, radiation dose to the lung is one of the most critical determinants of toxicity from radiation treatment. Early clinical experience with intensity modulated radiation therapy (IMRT) in the post-EPP setting resulted in a 46% fatal pneumonitis rate, highlighting the need for stringent dose constraints to be applied to the remaining contralateral lung, resulting in much lower rates of high-grade radiation pneumonitis.[11,12] These findings led to an increasing awareness of the need to minimize radiation exposure to the contralateral lung. One approach to minimize radiation to the contralateral lung is through the use of opposing anterior-posterior (AP/PA) photon beams with supplemental electrons to treat the medial and inferior regions of the hemithorax. This strategy has been shown to provide greater lung sparing than IMRT.[13] However, the complex dosimetry of the electron-photon technique as well as concerns for inadequate dose delivery to the medial and inferior regions supplemented with electrons have limited clinical use of this approach. Hemithoracic radiation with an intact ipsilateral lung has been feasible in small series, but pneumonitis remains a major concern.[14,15] Increasing use of P/D over EPP further increases the challenge of delivering safe and effective radiation therapy for mesothelioma treatment.[16] The role of radiation therapy in the management of mesothelioma was recently reviewed by the U.S. National Cancer Institute, International Association for the Study of Lung Cancer Research, and Mesothelioma Applied Research Foundation.[17]

The unique dosimetric characteristics of proton radiation compared with photon radiation can decrease radiation dose to critical structures such as the lungs and heart while delivering the prescribed dose to the target volume. Little data have been published on proton therapy for mesothelioma and technical challenges unique to proton therapy. This summary is the Particle Therapy Cooperative Group (PTCOG) Thoracic Subcommittee task group's review of proton therapy for malignant pleural mesothelioma.

Photon Therapy for Mesothelioma

Radiation therapy for pleural mesothelioma has evolved over the last several decades.[18] Because this cancer is uncommon, very few randomized trials have been conducted with radiation therapy as the primary focus. Single-institution studies or retrospective reviews have led to the current treatment paradigms for patients with mesothelioma. Aggressive therapies (surgery and adjuvant or neoadjuvant radiation therapy) are typically reserved for fit patients with stage I-III and the epithelioid subtype of mesothelioma.[19]

Conventional radiation therapy for mesothelioma began with 2-dimensional or 3-dimensional fields and

evolved at specialized centers to include AP/PA photon fields and matching electrons fields with blocks to protect the spinal cord, liver, stomach, kidneys, and heart.[13,20,21] Most initial reports included patients who had undergone EPP. Although acceptable, this technique was felt to be lacking in terms of coverage and dose homogeneity. As technology improved, so did radiation techniques. IMRT allows more conformal coverage of large and complex treatment volumes with the possibility of dose escalation, and as such its use to treat mesothelioma is increasing significantly, but it results in a large volume of uninvolved tissues receiving a "low-dose radiation bath."[22,23] After initial reports with unacceptably high rates of severe and fatal pneumonitis, dose constraints to the uninvolved lung emerged, with most centers applying a mean dose of less than 8 Gy to the contralateral lung to enhance safety.[11,24-28] A summary of select IMRT series in mesothelioma is shown in Table 1.[29,30]

SAKK17/04 was an international, multicenter, randomized, phase 2 trial conducted with radiation as the primary question. This study enrolled patients who had undergone R0 or R1 resection after EPP and neoadjuvant chemotherapy (cisplatin and pemetrexed) and randomized 54 patients to radiation or observation. The investigators found no difference in locoregional relapse-free survival and increased toxicity in those who received radiation.[31] Their controversial conclusion to not recommend radiation therapy after EPP has been questioned owing to the small numbers of patients enrolled, resulting in low power (the trial was closed early due to poor accrual) as well as lack of central review and shared dosimetric results.[32] There was no apparent advantage to the radiation therapy, but the trial was both underpowered and incomplete. However, EPP is being performed less frequently because many centers are increasingly performing P/D, with EPP now more commonly reserved only for select patients.[33]

Many centers have been reluctant to provide adjuvant radiation therapy to patients who have undergone P/D, as they have an intact lung underlying the radiation portal that is susceptible to radiation-induced lung injury. Treating the entire pleural surface of a lung safely is quite challenging. A pioneer in this area has been MSKCC. Their approach consists of comprehensive pleural IMRT and is known as intensity modulated pleural radiation therapy after P/D.[34] Their single-institution, single-arm studies have shown that this approach is safe (20% incidence of grade 3 pneumonitis with one treatment-related death), with median survival rates ranging from 17 to 26 months.[35] They also found that heart dose correlated strongly with symptomatic radiation pneumonitis; therefore, both lung and heart doses must be considered to minimize pneumonitis risk.[36] With a 2-year local failure rate of 74%, they stress the need for adequate initial surgery.[14] MSKCC also conducted a phase 2 study with MD Anderson Cancer Center using neoadjuvant chemotherapy followed by P/D and adjuvant IMRT and reported

median progression-free survival of 12.4 months and overall survival of 23.7 months.[34] This technique will be applied in an upcoming NRG Oncology cooperative group study randomizing patients to receive or not receive adjuvant intensity modulated pleural radiation therapy (NRG LU006). A recent randomized study presented at the European Society for Radiotherapy and Oncology 2019 meeting showed that for patients with incompletely resected mesothelioma after lung sparing surgery, radical hemithoracic radiation therapy (50 Gy hemithorax with 60 Gy to gross disease) improved 2-year overall survival from 28% to 58%, compared with palliative dose radiation, providing strong, high-level evidence that "definitive" dose radiation is beneficial in this patient population.[37]

For patients with unresectable disease, the role of radiation is frequently palliative. The National Comprehensive Cancer Network recommends palliation with doses of 20 to 40 Gy and with preference for a larger fraction size of 4 Gy.[19] Dr MacLeod et al from the University of Edinburgh conducted a multicenter, single-arm, phase 2 study looking at pain relief after 20 Gy in 5 fractions.[38] They found that 14 out of the 40 patients treated had a clinically meaningful improvement in their pain at 5 weeks after treatment. One typical palliative regimen is 25 to 30 Gy in 5 fractions for chest wall disease.[9]

Finally, de Perrot et al from the Princess Margaret Hospital are investigating the use of high doses of radiation therapy to the entire intact lung followed by EPP within 7 days for select patients with clinically node-negative disease; they call this protocol SMART (Surgery for Mesothelioma After Radiation Therapy).[39] In this single-arm, phase 2 study, patients who were fit for surgery underwent radiation therapy to 25 Gy to the entire lung and a simultaneous integrated boost of 5 Gy to gross disease. Patients who were found at surgery to have positive nodes went on to receive chemotherapy. The investigators reported a very promising median survival of 36 months. This study has not yet been replicated by other centers.

Conclusions

Toxicity from radiation treatment for mesothelioma remains a major challenge. Heart, lung, and often esophagus doses are high and predispose patients to life-threatening complications. Local control and survival remain poor. This leaves much room for improvement in therapy to both mitigate toxicity and increase efficacy.

Rationale for Proton Therapy in Mesothelioma

The physical properties of proton beam therapy are particularly advantageous for sparing of large radiosensitive thoracic organs-at-risk (lungs, heart, spinal cord,

Table 1 Select IMRT studies in mesothelioma

Authors (year)	Institution	Patient no.	Treatment	Survival	Radiation dose (median)	Lung dose	Toxicity
Post-EPP							
Rice et al.[27,28] (2007)	MD Anderson	63	EPP then IMRT, 8% neoadjuvant chemo	Median 14.2 mo	45 Gy in 25 fractions	Mean V20 Gy 4.9%; Mean MLD 8.3 Gy	13/63 noncancer related deaths during or within 6 months of IMRT
Kristensen et al.[29] (2009)	Copenhagen University Hospital	26	Chemo, then EPP, then IMRT	Not stated	50 Gy in 25 fractions with boost to 60 Gy	Median V20 Gy 13.9%; Median MLD 12.5 Gy	15% grade 5 lung toxicity
Giraud et al.[30] (2011)	Curie Institute and René Gauducheau Cancer Center	24	EPP then IMRT	Not stated	50 Gy in 25 fractions	Median V20 Gy 4%; Median MLD 11 Gy	2/24 (8%) grade 5 pneumonitis
Gomez et al.[12] (2013)	MD Anderson	86	EPP then IMRT, Chemo in 37% of patients	Median 14.7 mo	45-50 Gy in 25 fractions with boost to 55-60 Gy	Dose constraints: MLD < 8 Gy;	5/86 (5.8%) grade 5 toxicity, all pulmonary
Post-P/D (lung intact)							
Rosenzweig et al.[35] (2012)	Memorial Sloan Kettering	36	Chemo, then P/D or no surgery, then IMRT	Median 26 mo	46.8 Gy in 26 fractions	Dose constraints: MLD < 20 Gy;	20% grade 3+ pneumonitis (1 grade 5)
Minatel et al.[15] (2012)	Centro di Riferimento Oncologico of Aviano	28	P/D or biopsy, then chemo (for most patients), then IMRT.	Not stated	50 Gy in 25 fractions	Mean V20 Gy 36-38%; mean MLD 20-21 Gy; mean contralateral lung MLD 4-5 Gy	17.8% grade 2 or 3 pneumonitis
Rimner et al.[34] (2016)	Memorial Sloan Kettering and MD Anderson	27	Chemo, then P/D or no surgery, then IMRT	Median 23.7 mo	46.8 Gy in 26 fractions	Dose constraints: MLD < 21 Gy; V20 Gy < 37%; contralateral lung V20 Gy < 7%	30% grade 2 or 3 pneumonitis

Abbreviations: EPP = extrapleural pneumonectomy; IMRT = intensity modulated radiation therapy; MLD = mean lung dose; P/D = pleurectomy and decortication.

esophagus) when treating pleural mesothelioma. Proton therapy has the potential to both decrease toxicity and to dose escalation to the target to improve local control and survival. The ability to modulate the shape and intensity of the proton beam with intensity modulated proton therapy (IMPT) using scanning beam technology provides further advantages over passive scattering proton therapy. Lin et al demonstrated that scanning beam proton therapy achieved better tumor coverage and conformity of radiation dose with reduced dose to the lungs, esophagus, heart, and spinal cord compared with first-generation proton therapy using double scattering technique.[40]

Figures 1 through 4 provide dosimetric comparisons between photon IMRT plans and IMPT plans for 2 patients treated at MD Anderson Cancer Center. Figure 1 shows the 3-field IMPT plan for a patient post-EPP. The prescription dose was 50 Gy in 2 Gy fractions. Figure 2 shows the dosimetric comparison between the IMPT plan in Figure 1 and an IMRT plan for the same patient. Although both IMRT and IMPT plans had similar target coverage, the IMPT plan produced lower doses to the contralateral lung, heart, esophagus, liver, and kidneys. Importantly, mean dose to the contralateral lung was 4.8 Gy with IMRT and only 1.4 Gy with IMPT. The higher doses with IMRT mainly resulted from the low-dose bath, as the 2 plans had similar contralateral lung V20 and V10 values, but V5 was higher with IMRT (34.2% vs. 8.0%). Multiple studies have correlated lung dose and pulmonary toxicity after radiation for mesothelioma.[27,29] Rice et al found that multiple lung dose parameters correlated with pulmonary-related deaths, including mean lung dose, V20 Gy, V10 Gy, and absolute volume of lung spared from low dose radiation (5-10 Gy).[27] Kristensen et al also found that patients with pneumonitis had higher lung radiation dose than patients without pneumonitis, including V10 Gy and mean lung dose.[29] Proton therapy plans perform better on all of the aforementioned lung dosimetric parameters.

IMPT further led to a lower mean heart dose (12.6 Gy vs 28.2 Gy for IMRT), mean liver dose (12.6 Gy vs 29.1 Gy), and mean doses for the ipsilateral and contralateral kidneys (11.3 Gy vs 32.8 Gy, and 0.2 Gy vs 3.9 Gy, respectively). These are clinically meaningful decreases to these organs.[41,42]

Other groups have also found a clear dosimetric advantage to proton therapy over IMRT in the post-EPP setting. A summary of dosimetry comparisons between

Figure 1　Intensity modulated proton therapy plan for a patient with mesothelioma post−extrapleural pneumonectomy. Axial, coronal and sagittal images show the dose distribution for each of the 3 proton fields: (A) 15 degrees, (B) 180 degrees, (C) 280 degrees, and (D) composite dose. Multifield optimization was required to cover this complex volume. At least 2 beams contributed to dose at every voxel to maximize target uniformity and organ sparing. Fields A and C provided most of the dose to the anterior region; fields B and C provided most of the posterior coverage; and all 3 fields contributed to coverage superiorly. Although the dose from each beam is not uniform, the composite plan provides uniform dose coverage across the target.

Figure 2 Dosimetric comparison in post−extrapleural pneumonectomy setting. Intensity modulated proton therapy plan (top panel left) and IMRT plan (top panel right) for a patient post−extrapleural pneumonectomy are shown, with corresponding dose−volume histograms of the intensity modulated proton therapy plan (solid line, bottom panel) and IMRT plan (dashed line, bottom panel). The IMRT plan used 8 coplanar 6-MV beams (0°, 30°, 165°, 190°, 215°, 240°, 265°, 290°). Normal tissue constraints used included mean contralateral lung dose <5 Gy, maximum cord dose <45 Gy, mean esophagus dose <34 Gy, mean heart dose <26 Gy, and heart V30 Gy < 45%. Goal planning target volume coverage was that >95% of planning target volume receives at least the prescription dose. *Abbreviation:* IMRT = intensity modulated radiation therapy.

proton and photon therapy is shown in Table 2. Krayen-buehl et al performed a dosimetric comparison of IMPT versus IMRT in 8 patients with mesothelioma treated by EPP followed by IMRT. They found significant improvements in target coverage (V95) and reduced mean doses to kidneys, contralateral lung, heart, spinal cord, and liver with IMPT compared with IMRT.[43] A similar dosimetric comparison of IMRT to IMPT was performed by Lorentini et al in 7 patients treated with EPP and IMRT. The authors confirmed the findings of the previous analysis, noting significant reductions in several organs at risk with IMPT. In addition, using normal tissue complication probability modeling, they predicted significantly reduced risks of toxicities to the liver, kidneys, and esophagus with IMPT compared with IMRT. Likewise, a series from investigators at the University of Washington showed that in the post-EPP setting for hemithoracic radiation, IMPT radiation plans can deliver up to 66 Gy to the target volume while meeting normal

tissue dose constraints with contralateral mean lung doses of ≤1.5 Gy.[44] This is compared with photon volumetric arc therapy plans that would either have to exceed normal tissue dose limits to achieve similar target volume coverage or sacrifice target volume coverage to meet normal tissue constraints. A comparison of various spot sizes with IMPT found that larger spot sizes (sigma of 9 mm) are generally more robust compared with a small spot size (sigma of 3 mm), but resulted in slightly reduced target coverage while still meeting target coverage goals and dose constraints of OARs.[45] Robustness of smaller spot sizes may be mitigated through 4-dimensional (4D) robust optimization.

Less has been published on proton therapy in the post-P/D setting (with an intact ipsilateral lung). Figure 3 shows a proton IMPT plan for a patient post-P/D. The prescription dose was 50 Gy with 2 Gy per fraction. Owing to the large planning target volume (3276.4 cm³), a 2-isocenter technique with 4 beams was used in this

Figure 3 Intensity modulated proton therapy plan for a patient with mesothelioma post-pleurectomy and -decortication. Axial, coronal, and sagittal images show the dose distribution for each of the 4 proton fields: (A) 0 degrees, (B) 220 degrees, (C) 320 degrees, (D) 180 degrees, and (E) composite dose. Owing to the large planning target volume (3276 cm^3), a 2-isocenter technique with 4 beams was used to design a multifield optimization plan. The 2 isocenters were 5 cm apart to achieve maximum overlap and efficient daily set-up. The posterior beams, fields B and D, were assigned to the lower isocenter and covered the superior and posterior portion of the target volume. Two anterior beams, fields A and C, were assigned to the upper isocenter and covered the superior and anterior portion of the target volume. Multifield optimization was used to ensure uniform dose over the overlapping regions. Each beam was delivered in 4 to 7 minutes, for a total of 25 minutes of beam-on time for the 4-beam plan. Robust evaluation tools were used to analyze the intensity modulated proton therapy plan against 3-mm setup and 3.5% range uncertainties.

case to design a multifield optimization plan, although some of the newer proton machines can treat this volume without needing to split the fields, and 2 beams could be used to treat the volume. Figure 4 shows the dosimetric comparison between the IMPT plan in Figure 3 and a volumetric arc therapy plan for the same patient. The most challenging normal tissue constraint in this setting remains the ipsilateral lung dose. IMPT produced lower mean doses to the contralateral lung (0.1 vs. 2.9 Gy), heart (7.4 vs. 21.4 Gy), liver (14.8 vs. 29.0 Gy), ipsilateral kidney (2.6 vs. 11.2 Gy), and contralateral kidney (0.07 vs. 5.8 Gy). However, the mean dose for ipsilateral lung is slightly higher for the IMPT plan (48.7 vs. 46.3 Gy), largely owing to a slight increase in planning target

volume coverage for the IMPT plan. In post-P/D hemi-thoracic radiation, proton radiation can decrease dose to organs outside the target volume (contralateral lung, heart, liver, kidneys, etc) but not to the ipsilateral lung.

Conclusions

Compared with photon-based radiation techniques, proton therapy for mesothelioma can substantially reduce radiation dose to the contralateral lung (mean dose to contralateral lung often <1.5 Gy, V5 Gy <10%), which is associated with mortality and morbidity in mesothelioma treatment. Proton therapy also decreases mean heart, mean liver, and kidney doses by more than half. This is

Figure 4 Dosimetric comparison in the post-pleurectomy and -decortication setting. An intensity modulated proton therapy plan (top panel left) and IMRT plan (top panel right) are shown for a patient post-pleurectomy and -decortication, with corresponding dose—volume histograms of the intensity modulated proton therapy plan (solid line, bottom panel) and IMRT plan (dashed line, bottom panel). The IMRT plan used volumetric arc therapy with 2 arcs (181° to 37° clockwise with 10° collimator rotation and 35° to 183° count clockwise with 350° collimator rotation). *Abbreviation:* IMRT = intensity modulated radiation therapy.

true both in the post-EPP setting as well as the post-P/D setting. Proton therapy is expected to result in similar ipsilateral lung dose compared with photon therapy in the post-P/D setting owing to limited proton stopping power of the low-density lung tissue. Although there is no high-level comparative clinical data on proton therapy versus photon therapy for mesothelioma, the clear dosimetric advantages of proton therapy in this setting, especially IMPT, and the high mortality and morbidity risk associated with normal tissue dose in mesothelioma radiation therapy, means that IMPT should be strongly considered in this setting, when available, and delivered by experienced multidisciplinary management teams.

Challenges with Proton Therapy for Mesothelioma

Range uncertainty in protons

Proton beams have a characteristic Bragg Peak with a distinctive sharp dose falloff at the distal end. This makes proton beam therapy sensitive to range uncertainties. The proton range in tissue is associated with multiple sources of uncertainty, including uncertainty in converting computed tomography (CT) Hounsfield number to stopping power, patient setup, anatomic variation, and dose calculation. In addition, although dose calculations use a constant relative biological effectiveness (RBE) of 1.1 for protons, the RBE is potentially higher toward the distal end of the proton beam. The variable RBE effect can potentially extend the range up to 3 mm.[46] The use of a constant RBE of 1.1 is clinically employed because of the uncertainties in RBE and lack of RBE modeling in existing commercially available treatment-planning systems.[47]

To address the range uncertainties caused by CT imaging and patient setup, different proton centers have individual margin recipes to account for range uncertainties ranging from 2.5% of the range + 1.5 mm to 5% of the range + 5 mm.[47] For IMPT, ±3% in range and ±3-5 mm in patient setup uncertainties are often used for clinical target volume-based robust optimization or robustness analysis.

Table 2 Select proton dosimetric comparison studies in mesothelioma

Authors (year)	Patient no.	Radiation dose	Radiation techniques	Target coverage (protons vs photons)	Lung dose (protons vs photons)	Mean heart dose (protons vs photons), Gy	Mean liver dose (protons vs photons), Gy	Mean kidney dose (protons vs photons), Gy
Post-EPP								
Kreyenbuehl et al.[43] (2010)	8	45.5/55.9 Gy in 26 fractions to PTV2&1;	Proton: IMPT; Photon: IMRT	PTV1 V95%: 97% vs 95.4%	Mean dose: 0.4 vs 4.6 Gy; V20 Gy: 0.5 vs 2.9%	6.0 vs 25	3.7 vs 13.2	Contr: 0.1 vs 2.7; Ipsi: 7.0 vs 11.8
Lorentini et al.[45] (2012)	7	50/60 Gy in 25 fractions to PTV_{50} and PTV_{60}	Proton: IMPT; Photon: IMRT	PTV_{50} D99%: 47.1 vs 46.1 Gy	Mean dose: 0.2 vs 6.1 Gy; V20 Gy: 0.3 vs 5.8%	12.1 vs 24.6	14.2 vs 24.5	Contr: 0.0 vs 3.3; Ipsi: 14.3 vs 29.5
Lee et al.[44] (2017)	3	54 Gy in 30 fractions with boost to 60-66 Gy	Proton: IMPT; Photon: IMRT	Equal	Mean dose: 0.8 vs 15 Gy; V20 Gy: 0.8 vs 18%	10.0 vs 23.8	22.6 vs 31.5	Ipsi: 22.0 vs 26.3
Post-P/D (lung intact)								
Pan et al.[59] (2015)	7	45 Gy in 25 fractions with boost to 60 Gy	Proton: IMPT; Photon: IMRT	Not stated	Contr mean dose: 1.7 vs 5.0 Gy; Ipsi mean dose: 45.4 vs 47.6 Gy Total mean dose: 15.5 vs 18.8 Gy	14.5 vs 24.9	12.4 vs 24.8	Ipsi: 7.7 vs 15.6
This study	1	50 Gy in 25 fractions	Proton: IMPT; Photon: IMRT	PTV V90%: 100% vs 98%	Contr mean dose: 0.1 vs 2.9 Gy; Ipsi mean dose: 48.7 vs 46.3 Gy	7.4 vs 21.4	14.8 vs 29.0	Contr: 0.1 vs 5.8; Ipsi: 2.6 vs 11.2

Abbreviations: contr = contralateral; EPP = extrapleural pneumonectomy; IMPT = intensity modulated proton therapy; IMRT = intensity modulated radiation therapy; ipsi = ipsilateral; P/D = pleurectomy and decortication; PTV = planning target volume.

For treatment delivery, range shifters are generally needed to cover the target volume in the shallow region and a larger air gap may be used for treatment setup clearance. However, the analytical pencil beam dose calculation algorithm implemented in most proton treatment planning systems does not accurately account for the lateral inhomogeneity for each of the ray traces and the dose scattered from ranger shifters. Therefore, the use of a Monte Carlo dose calculation algorithm is preferred to ensure dose calculation accuracy.[48,49]

Organ motion

Proton beams are sensitive to the volume and density of tissue that is traversed on the way to the target. The potential dosimetric impact of respiratory motion, cardiac motion, and tissue density variation need to be addressed carefully.

IMPT is more sensitive to tumor motion compared with a compensator-based and passive-scattering techniques. Dose to the moving target can be affected by interference between the dynamic spot-by-spot scanning beam delivery and tumor motion, commonly known as the interplay effect.[50] Although the averaging effect over many fractions in a conventional fractionation scheme can reduce the interplay effect, 4D robust planning, increased spot sizes, layered rescanning, volumetric rescanning, breath holding and assisted breathing, and gating techniques have been used as mitigation strategies.[50-53] These strategies can effectively mitigate the interplay effect depending on the magnitude of tumor motion, tumor volume, and proton beam spot size.[52] In addition to 4D robust treatment planning, 4D robustness evaluation should be employed to assess the combined effect of possible uncertainties affecting IMPT treatments.[54] A detailed discussion of IMPT in the treatment of thoracic malignancies can be found in the recent consensus statement by PTCOG.[55]

For patients with malignant pleural mesothelioma after pleurectomy or decortication, tumor and normal tissue motion in the ipsilateral lung is typically minimal owing to limited diaphragmatic excursion or in the definitive setting due to tumor restricting respiratory excursion.[35] Nevertheless, target motion and motion of the contralateral lung should be assessed with 4D CT, and appropriate tumor motion mitigation strategies should be used, as needed.

Image guided radiation therapy (IGRT) and anatomy change

Onboard cone beam CT is ideal for online IGRT and can allow for deformable registration for ease of adaptive proton therapy, but it is not available at every proton center.[56] Onboard KV orthogonal imaging is acceptable for IGRT, as bony anatomy can be used as surrogates. However, the potential of anatomy change, including air volume and changes in pleural effusions in the hemithorax, for patients with mesothelioma receiving radiation therapy, can be significant. In patients who undergo EPP, the hemithorax will gradually fill with fluid in the postoperative period, especially in the first 8 weeks after surgery. This needs to be monitored during radiation therapy and can affect target coverage and doses to OARs.[43] The impact of this volume change is greater with protons than photons. Therefore, volumetric imaging either using onboard cone beam or regularly scheduled quality assurance CT scans should be used during the treatment course to monitor for anatomy changes. Adaptive replanning may be needed to adjust to the anatomy changes to ensure proper dose delivery.

Conclusions

When using proton therapy for mesothelioma, close attention must be paid to range uncertainty, organ motion, changes in anatomy, beam path tissue composition, and limitations in image guidance. Proton therapy for mesothelioma should preferentially be delivered at high-volume centers with specialized expertise.

Clinical Data on Proton Therapy for Mesothelioma

Although clinical data on outcomes of patients with mesothelioma after proton beam therapy are limited, early reports have demonstrated very promising treatment toxicity and disease control outcomes. The University of Washington reported a 3-case series of patients with mesothelioma receiving hemithoracic proton radiation post-EPP.[44] All 3 patients received neoadjuvant cisplatin/pemetrexed before EPP. Even with boost doses up to 66 Gy, treatment was well tolerated, and radiation pneumonitis was not observed. Mean dose to the contralateral lung was 0.3 Gy, 0.7 Gy, and 1.5 Gy for the 3 patients treated to 54 Gy to the hemithorax, with 1 patient receiving a 60-Gy boost and another patient receiving a 66-Gy boost.

The University of Pennsylvania reported their experience of 16 patients with unresectable mesothelioma treated with 17 proton therapy courses. Patients were predominantly male (81%) with epithelial histologic subtype (82%) and stage III-IV disease (94%). Patients were a median of 69.8 years old at the time of proton therapy, which was delivered a median of 11.1 months after mesothelioma diagnosis (range, 3.5-69.3 months). All patients received pemetrexed plus cisplatin or carboplatin before (n = 15) or concurrently with (n = 1)

proton therapy. Proton therapy was administered as adjuvant therapy after lung-sparing radical pleurectomy (n = 8) to sites of gross disease (but excluding the entire pleural surface) after progression on systemic therapy (n = 8) or as initial definitive therapy with concurrent chemotherapy (n = 1). Patients were treated to a median dose of 51.75 Gy (CGE) in 2.0-Gy (CGE) daily fractions (range, 50.0-75.0 Gy/1.8-2.5 Gy). All patients had durable local control throughout the follow-up period at a median follow-up of >5 months from proton therapy completion. At the time of reporting at International Association for the Study of Lung Cancer 16th World Conference on Lung Cancer, the median overall survival for the cohort had not yet been reached, and no patient developed any acute or late grade ≥3 toxicity. Across the 17 proton therapy courses, acute grade 2 toxicity included radiation dermatitis (n = 8), dysphagia or esophagitis (n = 4), anorexia (n = 3), fatigue (n = 2), and cough (n = 1). Late grade 2 toxicity included radiation pneumonitis in just 1 patient (6%). Overall, patients' Eastern Cooperative Oncology Group performance scores improved from proton therapy beginning to end (mean 1.2-0.9).[57] In a subsequent report, the same investigators prospectively treated 10 patients with proton therapy to a median of 55.0 CGE/1.8-2.0 CGE (range, 50-75 CGE) adjuvantly (n = 8) or as salvage therapy (n = 2) after P/D. Patients were predominantly male (90%) with epithelioid histology (100%) and stage III-IV disease (100%). Two-year local control was 90%, with distant and regional failure rates of 50% and 30%, respectively. Median survival from proton therapy completion was 19.5 months (30.3 months from diagnosis), and no patient experienced Common Terminology Criteria for Adverse Events v4 grade ≥2 acute or late toxicity.[58] The lack of severe toxicity is unique and important.

MD Anderson Cancer Center also reported on their experience using IMPT to treat 4 patients with mesothelioma with intact lungs, showing that the technique is safe and feasible.[59] IMPT plans produced lower doses to normal tissues compared with IMRT plans for the same patients. The dose reduction to the heart and contralateral lung were particularly notable. The University of Maryland reported on the first 10 consecutive patients treated with whole pleural IMPT for lung-intact malignant pleural mesothelioma.[60] Median-prescribed whole pleural dose was 45 Gy (range, 45.0-50.4 Gy/1.8-2.0 Gy), and median total dose was 54 Gy (range, 50.0-60.0 Gy/1.8-2.4 Gy). At a median follow-up of 6.5 months, treatment was well tolerated, with only 2 patients suffering grade 3 pneumonitis (20%) and no other severe (grade ≥3) toxicities. Six-month local control was 87.5% (95% confidence interval [CI], 76-99), progression free survival 31% (95% CI, 14-48), and overall survival 64.3% (95% CI, 48-81). A summary of clinical data on proton therapy has been added in Table 3.

Best Practice Recommendations for the Treatment of Mesothelioma with Proton Therapy

Based on the data presented herein, for patients undergoing radiation treatment for mesothelioma in the nonpalliative setting, we recommend intensity modulated proton therapy (IMPT) with scanning beam proton technology as the preferred proton delivery method. Although there are no high-level comparative clinical data on proton therapy versus photon therapy for mesothelioma, there are clear dosimetric advantages for proton therapy. The high mortality and morbidity risks associated with photon therapy strongly suggest that IMPT should be considered in this setting, when available, and delivered by experienced multidisciplinary management teams. Specific recommendations for steps of the treatment process follow. We also encourage readers to review the recent consensus guidelines on radiation therapy for mesothelioma by the U.S. National Cancer Institute, International Association for the Study of Lung Cancer Research, and Mesothelioma Applied Research Foundation,[17] and the NRG Oncology contouring atlases for lung cancer.

Simulation

All patients should undergo 4D CT-based simulation with motion evaluation with slice thickness ≤3 mm, scanning from at least C3 to below both kidneys (top of iliac crest). Patients are treated supine with their arms up with immobilization devices. For target volumes that exhibit more than a threshold of motion (typically >5 mm maximum), motion mitigation strategies should be employed, such as abdominal compression, breath hold, respiratory gating, and dose repainting techniques. The combined effect of possible uncertainties should be assed via 4D evaluation of the interplay effect for every patient.

Contouring

Gross disease should be contoured as gross tumor volume. The pleural surface is included in the clinical target volume, which typically includes a 5-mm rind of tissue from lung apex/thoracic inlet down to the insertion of the diaphragm posteriorly down to the T12-L1 vertebral body.[61] Pleura covering interlobar fissures, however, is not typically included unless grossly involved. Resection tracks and involved nodes are also included, but elective nodal irradiation is not recommended. Motion management of target volumes (internal gross tumor volume and internal clinical target volume) should be contoured per PTCOG consensus guidelines on implementing scanning beam proton therapy.[55]

Table 3   Select proton studies in mesothelioma

Authors (year)	Institution	Patient no.	Treatment	Survival	Radiation dose (median)	Lung dose	Toxicity
Post-EPP							
Lee et al.[44] (2017)	University of Washington	3	Chemo, then EPP, then IMPT	1 death at 4 mo post-RT; 1 death at 25 mo; 1 alive at 14 mo	54 Gy in 30 fractions with boost to 60-66 Gy	Mean dose: 0.8 Gy; V20 Gy: 0.8%	No grade 2+ pneumonitis
Post-P/D (lung intact)							
Pan et al.[59] (2015)	MD Anderson	4	P/D or biopsy then IMPT, all received chemo	Not stated	45 Gy in 25 fractions with boost to 60 Gy	Mean dose: 15.5 Gy; V20 Gy: 33.3%	Not stated
Li et al.[57] (2015)	University of Pennsylvania	16	P/D or biopsy then proton therapy, all received chemo	6-mo OS 35%; 12-mo OS 24%	51.75 Gy in 2.0 Gy daily fractions	Not stated	No grade 3+ toxicity; 1/16 (6%) grade 2 pneumonitis
Molitoris et al.[60] (2018)	University of Maryland	10	P/D or biopsy then IMPT, 9/10 patients received prior chemo	6-mo OS 64.3%	45 Gy in 1.8-2.0 Gy fractions with boost to 54 Gy	Not stated	20% grade 3 pneumonitis; 10% grade 2 pneumonitis
Rice et al.[58] (2019)	University of Pennsylvania	10	P/D then proton therapy (uniform or double scattering technology), all also received photodynamic therapy and chemo	Median 19.5 mo from end of RT; 1-y OS 58%; 2-y OS 29%	55 Gy in 1.8-2.0 Gy daily fractions	Not stated	No grade 3+ toxicity; 1/10 (10%) grade 2 pneumonitis;

Abbreviations: EPP = extrapleural pneumonectomy; IMPT = intensity modulated proton therapy; OS = overall survival; P/D = pleurectomy and decortication; RT = radiation therapy.

Treatment planning

Treatment planning is typically performed on the average CT scan but reviewed on additional phases (typically at least maximal inhalation and exhalation) to ensure coverage throughout the respiratory cycle, ideally with 4D robust optimization.[62] IMPT is highly recommended for mesothelioma treatment owing to the complicated target shape. Two to 4 fields are typically used in planning, most optimally with multifield optimization, with beam angles ranging from anterior to posterior, laterally around the ipsilateral chest (ie, left sided beams for treating a left sided tumor). The use of a Monte Carlo dose calculation algorithm for improved dose calculation accuracy is also preferred.

Target dose should be at least 45 Gy for microscopic disease and 60 Gy for gross disease. With proton therapy, dose escalation beyond 60 Gy is possible while still staying well below normal tissue dose constraints.[44,63] Relevant organs at risk include normal lungs, heart, liver, kidneys, esophagus, spinal cord, stomach, brachial plexus, and skin. Proton therapy can typically achieve contralateral mean lung dose <1.5 Gy with V20 Gy <5%, mean heart dose <15 Gy, mean liver dose <25 Gy (for right-sided tumors), ipsilateral kidney mean dose <18 Gy, contralateral kidney mean dose <1 Gy, mean esophagus dose <34 Gy, and spinal cord max 45 Gy. Although there are no specific dose constraints for the skin, plans should be optimized to minimize hot spots and dose to the skin rind. For patients being treated with 2 intact lungs in the post-P/D setting, the ipsilateral lung will receive almost the entire prescription dose, and this treatment should only be performed at high-volume centers or on a clinical trial. Total lung mean dose should be <20 Gy, when feasible; however, because the involved ipsilateral lung is likely to have limited function, it is critical to minimize dose to the contralateral lung, ideally mean lung dose <1.5 Gy as stated above. A summary of recommended dose constraints is listed in Table 4.

Onboard imaging and adaptive replanning

Daily cone beam CT is ideal for treatment of mesothelioma due to the potential for anatomic changes in the thoracic cavity during the several-week-long treatment course. Because many proton centers do not have this technology, daily kV-kV orthogonal pairs are also acceptable, with repeat verification quality assurance CT simulation at least once every 5 (ideal, especially in the first half of treatment) to 10 fractions to confirm stability in anatomy.[56,64] Because weeks can pass between simulation and treatment start, the first quality assurance scan should happen early in the treatment course (first week). When a rescan is done for quality assurance, the treatment plan should be run on the new rescan to ensure target coverage and normal tissue dose limits are still met. If there is a clinically meaningful decrease in coverage or increase in normal tissue dose, adaptive replanning should be performed.

Overall Recommendations

For patients receiving nonpalliative radiation therapy for mesothelioma, proton therapy is likely to be beneficial in terms of its ability to decrease radiation dose to the contralateral lung (the greatest potentially life-threatening toxicity risk in radiation therapy for mesothelioma), and other organs such as heart, liver, and kidneys. Proton therapy has clear dosimetric advantages over photon therapy. There are significant expertise requirements to delivering hemithoracic radiation with proton therapy owing to the large volume that needs to be treated, complex shape of the target, and organ motion, in addition to possible changes in tissue density during treatment. Proton therapy for mesothelioma, therefore, should preferably be delivered at high-volume centers with specialized expertise in delivering this treatment. IMPT is better suited for the complex tumor volume anatomy, but motion management strategies must be applied and adequate image guidance used. Dose reduction to normal tissues opens up possibilities of treatment intensification to improve outcomes, such as radiation dose escalation or combination with concurrent systemic therapy. The limited but growing clinical data reported to date on proton therapy for mesothelioma are promising, and more publications on the clinical experience of proton therapy for mesothelioma treatment are needed. The currently poor prognosis for patients with mesothelioma makes it imperative that strategies are explored to increase treatment efficacy, as well as decrease treatment toxicity to improve quality of life.

Table 4 Dosimetric constraints recommendations for proton plan with conventional fractionation

Target/normal organ	Criteria value
GTV	Prescription dose ≥60 Gy
CTV	Prescription dose ≥45 Gy
Contralateral lung	Mean dose <1.5 Gy; V20 Gy < 5%
Heart	Mean dose < 15 Gy
Liver	Mean dose < 25 Gy for right sided tumors; Mean dose < 1 Gy for left sided tumors
Ipsilateral kidney	Mean dose <18 Gy
Contralateral kidney	Mean dose < 1 Gy
Esophagus	Mean dose < 34 Gy
Spinal cord	Max 45 Gy
Skin	Minimize hot spots and contour skin rind

Abbreviations: CTV = clinical target volume; GTV = gross tumor volume.

References

1. Price B, Ware A. Time trend of mesothelioma incidence in the United States and projection of future cases: An update based on SEER data for 1973 through 2005. *Crit Rev Toxicol*. 2009;39:576-588.
2. Delgermaa V, Takahashi K, Park EK, Le GV, Hara T, Sorahan T. Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008. *Bull World Health Organ*. 2011;89:716-724, 724A-724C.
3. Musk AW, Olsen N, Alfonso H, et al. Predicting survival in malignant mesothelioma. *Eur Respir J*. 2011;38:1420-1424.
4. Sugarbaker DJ, Flores RM, Jaklitsch MT, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: Results in 183 patients. *J Thorac Cardiovasc Surg*. 1999;117:54-63. discussion 63-55.
5. Treasure T, Lang-Lazdunski L, Waller D, et al. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: Clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. *Lancet Oncol*. 2011;12:763-772.
6. Burt BM, Cameron RB, Mollberg NM, et al. Malignant pleural mesothelioma and the Society of Thoracic Surgeons Database: An analysis of surgical morbidity and mortality. *J Thorac Cardiovasc Surg*. 2014;148:30-35.
7. Flores RM, Pass HI, Seshan VE, et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: Results in 663 patients. *J Thorac Cardiovasc Surg*. 2008;135:620-626. e621-623.
8. Cao C, Tian D, Park J, Allan J, Pataky KA, Yan TD. A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma. *Lung Cancer*. 2014;83:240-245.
9. MacRae RM, Ashton M, Lauk O, et al. The role of radiation treatment in pleural mesothelioma: Highlights of the 14th International Conference of the International mesothelioma interest group. *Lung Cancer*. 2019;132:24-27.
10. Cramer G, Simone CB 2nd, Busch TM, Cengel KA. Adjuvant, neoadjuvant, and definitive radiation therapy for malignant pleural mesothelioma. *J Thorac Dis*. 2018;10:S2565-S2573.
11. Allen AM, Czerminska M, Janne PA, et al. Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma. *Int J Radiat Oncol Biol Phys*. 2006;65:640-645.
12. Gomez DR, Hong DS, Allen PK, et al. Patterns of failure, toxicity, and survival after extrapleural pneumonectomy and hemithoracic intensity-modulated radiation therapy for malignant pleural mesothelioma. *J Thorac Oncol*. 2013;8:238-245.
13. Hill-Kayser CE, Avery S, Mesina CF, et al. Hemithoracic radiotherapy after extrapleural pneumonectomy for malignant pleural mesothelioma: A dosimetric comparison of two well-described techniques. *J Thorac Oncol*. 2009;4:1431-1437.
14. Rimner A, Spratt DE, Zauderer MG, et al. Failure patterns after hemithoracic pleural intensity modulated radiation therapy for malignant pleural mesothelioma. *Int J Radiat Oncol Biol Phys*. 2014;90:394-401.
15. Minatel E, Trovo M, Polesel J, et al. Tomotherapy after pleurectomy/decortication or biopsy for malignant pleural mesothelioma allows the delivery of high dose of radiation in patients with intact lung. *J Thorac Oncol*. 2012;7:1862-1866.
16. Wolf AS, Flores RM. Current treatment of mesothelioma: Extrapleural pneumonectomy versus pleurectomy/decortication. *Thorac Surg Clin*. 2016;26:359-375.
17. Gomez DR, Rimner A, Simone CB 2nd, et al. The use of radiation therapy for the treatment of malignant pleural mesothelioma: Expert opinion from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. *J Thorac Oncol*. 2019;14:1172-1183.
18. Rosenzweig KE. Malignant pleural mesothelioma: adjuvant therapy with radiation therapy. *Ann Transl Med*. 2017;5:242.
19. National Comprehensive Cancer Network. Malignant pleural mesothelioma. Available at: https://www.nccn.org/professionals/physician_gls/pdf/mpm.pdf. Accessed May 30, 2020.
20. Baldini EH, Recht A, Strauss GM, et al. Patterns of failure after trimodality therapy for malignant pleural mesothelioma. *Ann Thorac Surg*. 1997;63:334-338.
21. Yajnik S, Rosenzweig KE, Mychalczak B, et al. Hemithoracic radiation after extrapleural pneumonectomy for malignant pleural mesothelioma. *Int J Radiat Oncol*. 2003;56:1319-1326.
22. Shaaban SG, Verma V, Choi JI, et al. Utilization of intensity-modulated radiation therapy for malignant pleural mesothelioma in the United States. *Clin Lung Cancer*. 2018;19:e685-e692.
23. Krayenbuehl J, Oertel S, Davis JB, Ciernik IF. Combined photon and electron three-dimensional conformal versus intensity-modulated radiotherapy with integrated boost for adjuvant treatment of malignant pleural mesothelioma after pleuropneumonectomy. *Int J Radat Oncol Biol Phys*. 2007;69:1593-1599.
24. Ashton M, O'Rourke N, Currie S, Rimner A, Chalmers A. The role of radical radiotherapy in the management of malignant pleural mesothelioma: A systematic review. *Radiother Oncol*. 2017;125:1-12.
25. Chi A, Liao Z, Nguyen NP, et al. Intensity-modulated radiotherapy after extrapleural pneumonectomy in the combined-modality treatment of malignant pleural mesothelioma. *J Thorac Oncol*. 2011;6:1132-1141.
26. Komaki R, Liao Z, Liu H, Tucker S, Rice D. Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma: in regard to Allen et al. (Int J Radiat Oncol Biol Phys. 2006;65:640-645). *Int J Radat Oncol Biol Phys*. 2006;66:1595-1596. author reply 1596.
27. Rice DC, Smythe WR, Liao Z, et al. Dose-dependent pulmonary toxicity after postoperative intensity-modulated radiotherapy for malignant pleural mesothelioma. *Int J Radat Oncol Biol Phys*. 2007;69:350-357.
28. Rice DC, Stevens CW, Correa AM, et al. Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma. *Ann Thorac Surg*. 2007;84:1685-1692. discussion 1692-1683.
29. Kristensen CA, Nottrup TJ, Berthelsen AK, et al. Pulmonary toxicity following IMRT after extrapleural pneumonectomy for malignant pleural mesothelioma. *Radiother Oncol*. 2009;92:96-99.
30. Giraud P, Sylvestre A, Zefkili S, et al. Helical tomotherapy for resected malignant pleural mesothelioma: dosimetric evaluation and toxicity. *Radiother Oncol*. 2011;101:303-306.
31. Stahel RA, Riesterer O, Xyrafas A, et al. Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): A randomised, international, multicentre phase 2 trial. *Lancet Oncol*. 2015;16:1651-1658.
32. Rimner A, Simone CB 2nd, Zauderer MG, Cengel KA, Rusch VW. Hemithoracic radiotherapy for mesothelioma: Lack of benefit or lack of statistical power? *Lancet Oncol*. 2016;17:e43-e44.
33. Verma V, Ahern CA, Berlind CG, et al. National Cancer Database report on pneumonectomy versus lung-sparing surgery for malignant pleural mesothelioma. *J Thorac Oncol*. 2017;12:1704-1714.
34. Rimner A, Zauderer MG, Gomez DR, et al. Phase II study of hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) as part of lung-sparing multimodality therapy in patients with malignant pleural mesothelioma. *J Clin Oncol*. 2016;34:2761-2768.
35. Rosenzweig KE, Zauderer MG, Laser B, et al. Pleural intensity-modulated radiotherapy for malignant pleural mesothelioma. *Int J Radat Oncol Biol Phys*. 2012;83:1278-1283.
36. Yorke ED, Jackson A, Kuo LC, et al. Heart dosimetry is correlated with risk of radiation pneumonitis after lung-sparing hemithoracic

pleural intensity modulated radiation therapy for malignant pleural mesothelioma. *Int J Radat Oncol Biol Phys*. 2017;99:61-69.

37. Minatel E, Trovo M, Polesel J, et al. Radical hemi-thoracic radiotherapy vs. palliative radiotherapy for malignant pleural mesothelioma. *Radiother Oncol*. 2019;133:S257.

38. MacLeod N, Chalmers A, O'Rourke N, et al. Is radiotherapy useful for treating pain in mesothelioma?: A phase II trial. *J Thorac Oncol*. 2015;10:944-950.

39. de Perrot M, Feld R, Leighl NB, et al. Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma. *J Thorac Cardiovasc Surg*. 2016;151:468-473.

40. Lin L, Kang M, Huang S, et al. Beam-specific planning target volumes incorporating 4D CT for pencil beam scanning proton therapy of thoracic tumors. *J Appl Clin Med Phys*. 2015;16:5678.

41. Wang K, Eblan MJ, Deal AM, et al. Cardiac toxicity after radiotherapy for stage III non-small-cell lung cancer: Pooled analysis of dose-escalation trials delivering 70 to 90 Gy. *J Clin Oncol*. 2017;35:1387-1394.

42. Dawson LA, Kavanagh BD, Paulino AC, et al. Radiation-associated kidney injury. *Int J Radat Oncol Biol Phys*. 2010;76:S108-S115.

43. Krayenbuehl J, Hartmann M, Lomax AJ, Kloeck S, Hug EB, Ciernik IF. Proton therapy for malignant pleural mesothelioma after extrapleural pleuropneumonectomy. *Int J Radat Oncol Biol Phys*. 2010;78:628-634.

44. Lee H, Zeng J, Bowen SR, Rengan R. Proton therapy for malignant pleural mesothelioma: A three case series describing the clinical and dosimetric advantages of proton-based therapy. *Cureus*. 2017;9:e1705.

45. Lorentini S, Amichetti M, Spiazzi L, et al. Adjuvant intensity-modulated proton therapy in malignant pleural mesothelioma. A comparison with intensity-modulated radiotherapy and a spot size variation assessment. *Strahlenther Onkol*. 2012;188:216-225.

46. Carabe A, Moteabbed M, Depauw N, Schuemann J, Paganetti H. Range uncertainty in proton therapy due to variable biological effectiveness. *Phys Med Biol*. 2012;57:1159-1172.

47. Paganetti H. Range uncertainties in proton therapy and the role of Monte Carlo simulations. *Phys Med Biol*. 2012;57:R99-R117.

48. Saini J, Traneus E, Maes D, et al. Advanced proton beam dosimetry part I: Review and performance evaluation of dose calculation algorithms. *Transl Lung Cancer Res*. 2018;7:171-179.

49. Maes D, Saini J, Zeng J, Rengan R, Wong T, Bowen SR. Advanced proton beam dosimetry part II: Monte Carlo vs. pencil beam-based planning for lung cancer. *Transl Lung Cancer Res*. 2018;7:114-121.

50. Grassberger C, Dowdell S, Lomax A, et al. Motion interplay as a function of patient parameters and spot size in spot scanning proton therapy for lung cancer. *Int J Radat Oncol Biol Phys*. 2013;86:380-386.

51. Knopf AC, Hong TS, Lomax A. Scanned proton radiotherapy for mobile targets-the effectiveness of re-scanning in the context of different treatment planning approaches and for different motion characteristics. *Phys Med Biol*. 2011;56:7257-7271.

52. Grassberger C, Dowdell S, Sharp G, Paganetti H. Motion mitigation for lung cancer patients treated with active scanning proton therapy. *Med Phys*. 2015;42:2462-2469.

53. Kardar L, Li Y, Li X, et al. Evaluation and mitigation of the interplay effects of intensity modulated proton therapy for lung cancer in a clinical setting. *Pract Radiat Oncol*. 2014;4:e259-e268.

54. Ribeiro CO, Meijers A, Korevaar EW, et al. Comprehensive 4D robustness evaluation for pencil beam scanned proton plans. *Radiother Oncol*. 2019;136:185-189.

55. Chang JY, Zhang X, Knopf A, et al. Consensus guidelines for implementing pencil-beam scanning proton therapy for thoracic malignancies on behalf of the PTCOG Thoracic and Lymphoma Subcommittee. *Int J Radat Oncol Biol Phys*. 2017;99:41-50.

56. Veiga C, Janssens G, Teng CL, et al. First clinical investigation of cone beam computed tomography and deformable registration for adaptive proton therapy for lung cancer. *Int J Radat Oncol Biol Phys*. 2016;95:549-559.

57. Li YR, Alley EW, Friedberg JS, et al. Prospective assessment of proton therapy for malignant pleural mesothelioma. *J Thorac Oncol*. 2015;10:S224.

58. Rice SR, Li YR, Busch TM, et al. A novel prospective study assessing the combination of photodynamic therapy and proton radiation therapy: Safety and outcomes when treating malignant pleural mesothelioma. *Photochem Photobiol*. 2019;95:411-418.

59. Pan HY, Jiang S, Sutton J, et al. Early experience with intensity modulated proton therapy for lung-intact mesothelioma: A case series. *Pract Radiat Oncol*. 2015;5:e345-e353.

60. Molitoris JK, Glass E, Miller K, et al. Toxicities and clinical outcomes of whole pleural intensity-modulated proton therapy for lung-intact malignant pleural mesothelioma. *Int J Radat Oncol Biol Phys*. 2018;102. Supplement, e664.

61. Forster KM, Smythe WR, Starkschall G, et al. Intensity-modulated radiotherapy following extrapleural pneumonectomy for the treatment of malignant mesothelioma: clinical implementation. *Int J Radat Oncol Biol Phys*. 2003;55:606-616.

62. Liu W, Schild SE, Chang JY, et al. Exploratory study of 4D versus 3D robust optimization in intensity modulated proton therapy for lung cancer. *Int J Radat Oncol Biol Phys*. 2016;95:523-533.

63. Badiyan SN, Molitoris JK, Zhu M, Glass E, Diwanji T, Simone CB 2nd. Proton beam therapy for malignant pleural mesothelioma. *Trans Lung Cancer Res*. 2018;7:189-198.

64. Chang JY, Li H, Zhu XR, et al. Clinical implementation of intensity modulated proton therapy for thoracic malignancies. *Int J Radat Oncol Biol Phys*. 2014;90:809-818.